This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Registry of Translarna (Ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy

This study is currently recruiting participants.
See Contacts and Locations
Verified February 2017 by PTC Therapeutics
Sponsor:
Collaborators:
TREAT-NMD
Cooperative International Neuromuscular Research Group (CINRG)
Information provided by (Responsible Party):
PTC Therapeutics
ClinicalTrials.gov Identifier:
NCT02369731
First received: January 28, 2015
Last updated: February 13, 2017
Last verified: February 2017
  Purpose
This study is being performed as a post-approval safety study (PASS), per the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA), to gather data on Translarna (ataluren) safety, effectiveness, and prescription patterns in routine clinical practice.

Condition Intervention
Muscular Dystrophy, Duchenne Drug: Translarna

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 5 Years
Official Title: Long-Term Observational Study of Translarna Safety and Effectiveness in Usual Care

Resource links provided by NLM:


Further study details as provided by PTC Therapeutics:

Primary Outcome Measures:
  • Incidence of adverse events [ Time Frame: 5 years ]

Secondary Outcome Measures:
  • Changes in laboratory parameters [ Time Frame: 5 years ]
  • Changes in blood pressure [ Time Frame: 5 years ]
  • Prescriber and patient compliance with prescribing information according to the approved labelling [ Time Frame: 5 years ]

Other Outcome Measures:
  • Patient health management measures [ Time Frame: 5 years ]

Estimated Enrollment: 200
Study Start Date: April 2015
Estimated Study Completion Date: April 2022
Estimated Primary Completion Date: April 2022 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Translarna
    Other Names:
    • Ataluren
    • PTC124
Detailed Description:
This is a multicenter, observational study of patients receiving Translarna based on inclusion of their data in a registry. This study is intended to enroll 200 patients across ~50 care centers in Europe and other regions over a period of ~ 2 years. The study population will include patients who are receiving usual care treatment with commercial supply of Translarna (or receiving care within a named patient early access program) and who provide consent. Patients will be followed for at least 5 years from their date of enrollment. Safety and efficacy data will be collected in conjunction with routine visits conducted as per usual care. Although there are no protocol-mandated procedures, it is expected that physicians and other caregivers will follow published treatment guidelines and standards of care.
  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
The target study population will include patients for whom the decision to prescribe Translarna (outside of a clinical trial) has already been made, including patients in named patient early access programs. Patients within each prescriber's practice who are or will be receiving treatment with Translarna, and who meet the eligibility criteria and provide informed consent (either by the patient or through authorisation by a legal guardian), will be invited to enroll into the study and will be followed according to the protocol.
Criteria

Inclusion Criteria:

  • Receiving or will be receiving usual care treatment with commercial supply of Translarna (or receiving care within a named patient early access program)
  • Willing to provide written informed consent to allow the study data collection procedures (either by the patient or through authorisation by a legal guardian)

Exclusion Criteria:

  • Patients who are receiving ataluren or placebo in a blinded, randomized clinical trial, or ataluren in any other ataluren clinical trial or cohort early access program that prevents participation in this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02369731

Contacts
Contact: Abdallah Delage adelage@ptcbio.com

Locations
Austria
Krankenhaus der Barmherzigen Schwestern Linz Recruiting
Linz, Austria, 4010
Principal Investigator: Veronika Pilshofer, Dr         
Preyer Children Hospital Recruiting
Wien, Austria, 1100
Principal Investigator: Guenther Bernert, Pr         
France
CHU Brest, hôpital Morvan Recruiting
Best, France, 29609
Principal Investigator: Ropars Juliette, Dr         
CHU Bordeaux Pelgrin Recruiting
Bordeaux Cedex, France, 33076
Principal Investigator: Caroline Espil-Taris         
L'Escale Hôpital Femme Mère Enfant- Hospices Civils de Lyon Recruiting
Bron, France, 69500
Principal Investigator: Carole Vuillerot, Dr         
CHU Clermont-Ferrand, hôpital Estaing Recruiting
Clermont-Ferrand, France, 63003
Principal Investigator: Catherine Sarret, Dr         
CHU de Martinique - Hôpital P. Zobda-Quitman Recruiting
Fort De France Cedex, France, 97261
Principal Investigator: Rémi Bellance, Dr         
CHRU de Lille Recruiting
Lille Cedex, France, 59037
Principal Investigator: Jean-Marie Cuisset, Dr         
CHU Marseille Hôpital de la Timone Recruiting
Marseille Cedex 5, France, 13385
Principal Investigator: Brigitte Chabrol, Pr         
CHU Nantes Recruiting
Nantes, France, 44000
Principal Investigator: Yan Pereon, Pr         
Hôpital Armand Trousseau Recruiting
Paris, France, 75012
Principal Investigator: Gidaro Teresa, Dr         
Hôpital Necker Recruiting
Paris, France, 75015
Principal Investigator: Isabelle Desguerre, Pr         
CHU Reims Recruiting
Reims, France, 51100
Principal Investigator: Pascal Sabouraud, Dr         
CHU Saint-Etienne MPR pédiatrique Hôpital Bellevue Recruiting
Saint Etienne Cedex, France, 42055
Principal Investigator: Stéphane Chabrier, Dr         
CHU de la Réunion - GHSR - GH Sud-Réunion Recruiting
Saint Pierre, France, 97448
Principal Investigator: Renouil Michel, Dr         
CHU Strasbourg Recruiting
Strasbourg Cedex, France, 67098
Principal Investigator: Vincent Laugel, Pr         
CHU Toulouse Recruiting
Toulouse, France, 31059
Principal Investigator: Pascal Cintas, Dr         
Hôpital d'enfants Gatien de Clocheville Recruiting
Tours Cedex 9, France, 37044
Principal Investigator: Lagrue Emmanuelle, Dr         
CHU Nancy Hôpital de Brabois-Enfants Rue du Morvan Recruiting
Vandoeuvre-les-Nancy, France, 54500
Principal Investigator: Emmanuel Raffo, Pr         
Germany
Klinikum Bayreuth GmbH Recruiting
Bayreuth, Germany, 95445
Principal Investigator: Almut Hirsch, Dr         
Charité Universitätsmedizin Berlin Recruiting
Berlin, Germany, 13353
Principal Investigator: Claudia Weiss, Dr         
Universitätsklinikum Erlangen Recruiting
Erlangen, Germany, 91054
Principal Investigator: Regina Trollmann, Pr         
Universitaetsklinikum Essen (AoR) Recruiting
Essen, Germany, 45147
Principal Investigator: Ulrike Schara, Pr         
SPZ Frankfurt Mitte Recruiting
Frankfurt am Main, Germany, 60316
Principal Investigator: Jurgen Seeger, Dr         
Universitaetsklinikum Freiburg Recruiting
Freiburg, Germany, 79106
Principal Investigator: Janbernd Kirschner, Pr         
UKE, Universitätsklinikum Hamburg-Eppendorf Recruiting
Hamburg, Germany, 20246
Principal Investigator: Jessica Johannsen, Dr         
Israel
Hadassah Medical Center Recruiting
Jerusalem, Israel, 91120
Principal Investigator: Talya Dor, Dr         
Chaim Sheba Medical Center Ramat Gan, Neuromuscle clinic Recruiting
Ramat Gan, Israel, 52621
Principal Investigator: Amir Dori, Dr         
Sweden
Queen Silvia Children's Hospital Recruiting
Goteborg, Sweden, 41685
Principal Investigator: Mar Tulinius, Pr         
Sponsors and Collaborators
PTC Therapeutics
TREAT-NMD
Cooperative International Neuromuscular Research Group (CINRG)
Investigators
Study Director: Robert Spiegel, MD PTC Therapeutics
  More Information

Responsible Party: PTC Therapeutics
ClinicalTrials.gov Identifier: NCT02369731     History of Changes
Other Study ID Numbers: PTC124-GD-025o-DMD
Study First Received: January 28, 2015
Last Updated: February 13, 2017

Additional relevant MeSH terms:
Muscular Dystrophies
Muscular Dystrophy, Duchenne
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked

ClinicalTrials.gov processed this record on August 18, 2017